Prostate Cancer

Alliance targets development of vesicular stomatitis virus-based therapeutics

Published in Cancer Weekly, February 25th, 2003

GTx, Inc. announced that it has entered into a cross-license and commercial option agreement with Wyeth (WYE) for vesicular stomatitis virus (VSV)-based technologies.

Wyeth has exclusively sublicensed to GTx patents covering VSV as cytolytic agents for use with proprietary VSV-based products of GTx. In return, Wyeth has an option to commercially license GTx's VSV-based anti-HIV product, GTx-v311. GTx has also granted to Wyeth a nonexclusive license to GTx's VSV vaccine technology, where recombinant VSV is used as vector for delivery of vaccine antigens.

GTx, Inc., is currently developing VSV technologies for use as targeted viral cytolytic agents...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-02-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry